Toggle Main Menu Toggle Search

Open Access padlockePrints

Recommended Methods for the Collection of Clinical Expert Judgment in Rare Diseases: Generating Evidence to Support Reimbursement of Orphan Drugs

Lookup NU author(s): Professor Kevin WilsonORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

Background: Developing rare disease therapies is challenging due tolimited evidence and high degrees of uncertainty regarding the value ofnew treatments. Clinical expert judgment can inform modellingassumptions and address areas of uncertainty in reimbursementsubmissions. As current protocols do not adequately address thechallenges faced in rare diseases, this research aimed to generaterecommendations for the collection and reporting of clinical expertjudgment in rare diseases.Methods: An international group of industry, payer and patient expertswith a background in rare diseases participated in a roundtable meeting,which aimed to identify practical challenges and solutions for gatheringclinical insights to aid reimbursement decisions for rare disease therapies.Recommendations were co-created through iterative discussions andconsensus.Results: Developers should proactively identify uncertainties that expertjudgment can address, in parallel with early evidence generationplanning. Expert judgment method(s) depend on the uncertainties, withthose key to decision-making requiring more robust and time-intensivemethods. For highly complex and uncertain topics, methods shouldfacilitate consensus-building and expression of diverse views. Given thescarcity of rare disease experts, a high time burden falls on few experts.Developers should engage diverse stakeholder groups to integratebroader clinical perspectives and reduce reliance on specific individuals,whilst approaching conflicts of interest pragmatically and transparently.Conclusion: These recommendations create a blueprint for developers ofrare disease therapies to conduct high-quality clinical expert judgmentstudies. In doing so, developers can present more robust evidence toinform key areas of uncertainty in reimbursement decisions, whereempiric evidence is unavailable.


Publication metadata

Author(s): Griffiths A, Dunning L, Facey K, Jankovic D, Gonzalez MC, Low E, Meregaglia M, Schmidt F, Wilson K, Upadhyaya S, Chapman N, Zentai C, Wright S, Newell I

Publication type: Article

Publication status: Published

Journal: International Journal of Technology Assessment in Health Care

Year: 2025

Volume: 41

Issue: 1

Online publication date: 07/10/2025

Acceptance date: 19/08/2025

Date deposited: 20/10/2025

ISSN (print): 0266-4623

ISSN (electronic): 1471-6348

Publisher: Cambridge University Press

URL: https://doi.org/10.1017/S0266462325100457

DOI: 10.1017/S0266462325100457

Data Access Statement: The supplementary material for this article can be found at http://doi.org/10.1017/S0266462325100457


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Costello Medical

Share